Consider a clinical trial in which the main end-point is survival. 
Introduction
An intermediate event is common and has recently got much attention in a controlled clinical study with survival as an end-point. For survival data in clinical studies refer to Lee (1994 Lee ( , 1998 and Lee and Sather (1995) . As noticed by many researchers such as Lagakos (1976) , Finkelstein and Scheonfeld (1994) , Fleming et al. (1994) , Lefkopoulou and Zelen (1995) and Nan et al. (2005) the intermediate event which is expected to confer survival advantage may have more important effect on survival than the treatment in many clinical situations. For example, consider the problem if chemotheraphies given to patients having cancer, have an effect on the survival. In most cases, this is also evaluated by the reduction of tumor size which may appear as the response of the treatment. Anderson et al. (1983) studied its relationship with survival. Another example is the analysis of Stanford heart transplant data set by Crowley and Hu (1977) . They consider the time-dependent Cox regression model λ(t | x, Y (t)) = λ 0 (t) exp β 1 x + β 2 Y (t) , (1.1) where t is the survival time, λ 0 (t) is the unspecified baseline hazard function, x is a baseline covariate and Y (t) is a time-dependent indicator for the occurrence of a given intermediate event defined by Crowley and Hu (1977) , most of studies on intermediate event are on testing its effect to survival time by treating it as an additional covariate. And less attention is given to testing treatment effect, which surely the main goal of the entire clinical study. The same is true for series of recent work by Nam and Zelen (2001) and Lefkopoulou and Zelen (1995 Crowley and Hu (1977) .
We expect this two-stage model will provide a power gain in testing treatment effect. However, due to the hierarchical structure of the model, the null hypothesis we test becomes a union of simple subspaces. Further, as will be shown in later, dimension of each subspace is not same. Due to these reasons, the most beloved likelihood ratio test(LRT) has difficulty in computation and its null distribution is not understood well. In this paper, we propose an alternative test procedure which has two-stage.
The two-stage procedure(TSP) we propose combines two LRTs of each stage of the proposed two-stage model: two LRTs are obtained from the story of logistic regression model and the proportional hazards model. A main difficulty of TST arises from controlling overall significance level. To resolve this difficulty, we utilize the fact that "two LRT statistics are independent to each other". This paper is organized as follows. In Section 2, the two-stage model is presented in order to model intermediate event and TSP is also presented. Section 3 provides the numerical simulations. The paper concludes with a discussion.
A Two-Stage Model and Its Procedure

A two-stage model
To assess the treatment effect on the survival time controlling for intermediate event, Nam and Zelen (2001) assume that the survival distribution for treatment belongs to a family of Lehmann's alternatives for each response level which naturally corresponds to the model in (1.1). This model treats the intermediate event as one of covariates in the model. Here, this model can be rewritten and extended to the model with interaction effect between covariate and intermediate event: 
where f (t | y, x) is modeled as in (2.1) and f (y | x) can be assumed to have the probability function given x as
This model may involve more interesting settings concerning the relationship between the treatment, intermediate event and survival. For example, consider the situation the survival is independent of treatment conditional on the occurrence of intermediate event.
That is, f (t | x, y = 1) = f (t | y = 1) and f (t | x, y = 0) = f (t | y = 0) implies that the comparing treatment is done by comparing the equality of f (y | x = 0) and f (y | x = 1) which represents the possibility of indirect treatment effect. To test the overall effect of the treatment on the survival time, we think of a direct effect following a path X → T and an indirect effect X → Y → T displayed in Figure 2 .1. To do this in the model (2.2) applying (2.1) and (2.3), the null hypothesis can be displayed as a circle in Figure  2 .2. The null hypothesis depicted as a circle(β 1 = β 3 = 0) means no treatment effect if we only consider the model (2.1). However, this is not enough to take effect into account since a covariate could affect to the survival time indirectly via the relationship with intermediate event.
Thus, the null hypothesis we are interested in should be the shaded region of the circle in Figure 2 .2. One is the null situation of H 0A : β 1 = β 3 = β 0 = β 2 = 0 which implies no treatment effect on survival times conditional on the response which has no effect on the survival and this response are not affected by the treatment. The other situation is that H 0B : β 1 = β 3 = β 0 = 0, β 2 = 0 which check if the treatment affects the survival time directly and indirectly via the occurrence of intermediate event which affect the survival time. The third situation is that H 0C : β 1 = β 3 = β 2 = 0, β 0 = 0 which means that β 1 = β 3 = 0 still works but the treatment Figure 2 .2: This is null parameter space which is representative of situation where there is no treatment effect on survival time affects the occurrence of intermediate event which also affects the survival time. As a result, the interesting parameter space for testing treatment effect can be described as Figure 2 .2). Here, the null hypothesis we test becomes a noncompact composite set which makes usual LRT difficult by means of commercial software. Moreover, the model in (2.1) cannot explain the indirect relationship resulting from the relationship between treatment and an intermediate event and it leads to the lose of power. Hence, we need to propose an alternative test procedures for this null parameter space: one is for testing the effect of treatment on the intermediate event and the other is for testing the effect of treatment and intermediate event on the survival time depending on the result of first procedure. In this paper we investigate these two procedures as a two-stage test procedure.
A two-stage procedure
In this section, we propose a two-stage procedure to test the treatment effect. The null hypotheses is broken down into two sequence of hypotheses and tested sequentially according to result of the first step: (i) the conditional distribution of Y given X is that in (2.3) and (ii) the conditional distribution of T given Y and X is that in (2.1). Firstly, we consider testing effect of covariate X on an intermediate event Y , i.e., H 0A : β 0 = 0. According to the result of the first step, we will take different hypothesis. If the null hypothesis is accepted, the next step has sequential hypothesis of H 0B : β 1 = β 3 = 0. Otherwise, the sequential hypothesis will be H 0C : β 1 = β 2 = β 3 = 0. This step is depicted in Figure 2 .3. We call this two-stage procedure in this paper. Now we introduce notations and test statistics to be used in the two-stage procedure. Let H 0A , H 0B and H 0C be the set of parameter values for hypothesis, H 0A , H 0B and H 0C respectively. We let H 0 = H 0A ∪ H 0B ∪ H 0C and let H be the set of all possible parameter values θ, β), where θ = (α, β 0 ) and β = (β 1 , β 2 , β 3 ) in (2.1) and (2.3). Let T i and C i be the survival time and the right-censoring time of the i th subject for i = 1, 2, . . . , n and 
. Then, the log-likelihood function becomes
where
and
Based on the log likelihood in (2.4), we may choose the well-known LRT statistics for each hypothesis H 0A , H 0B and H 0C . Hence, for each hypothesis, we let the LRT as V 1 , V 2 and V 3 as 
As shown in Figure 2 .3, the final rejection region
by the result of first stage. To do this, it however requires to control the overall significance level throughout the two-stage procedures.
Concerning the significance level in each stage, we apply the level k 1 in the first stage procedure and the level k 2 in the second stage procedure and to evaluate the significance level we generate the data from each null, H 0A , H 0B and H 0C . Under the data generated by the null H 0A , the significance level is calculated by
(2.8)
Note that the test statistic V 1 is independent of V 2 and V 3 . We get k 2 level if the data is generated from H 0A . Secondly, consider the data under the null H 0B . In this situation, the probability of rejection region V 3 > c 3 will be different from that in H 0A . Since the parameter space includes β 2 = 0, the probability of that region has the power γ 1 . Hence, the significance level is given by
Lastly, consider the data under the null H 0C . As similarly in H 0B , the probability of rejection region V 1 > c 1 will be the power γ 2 under β 0 = 0. Therefore, the significance level is calculated by
(2.10) 
In the above, the power γ 1 will be between α and one. If we let this equal to one so that its significance level set to maximum, then the feasible set of (k 1 , k 2 ) satisfying a size α test is shown as in Figure 2 .4.
Numerical Simulation Studies
In this section, we numerically investigate the overall significance level and power of the proposed test at fixed level. We first introduce the set up of the simulation. We generated n survival times T which are exponentially distributed with λ 0 (t) = 1 in (2.1). Censoring times are generated to yield about 30% of censored observations. Empirical significance levels and powers of the two-stage procedures were evaluated based on 1000 simulations with the data from the null H 0A , H 0B and H 0C respectively at the specific level k 1 and k 2 . For the generation of data from the null H 0A , we set β 0 = 0, β 2 = 0. We also set β 0 = 0, β 2 = 1 for generation from the null H 0B and β 0 = 1, β 2 = 0 for the null H 0C . We get β 0 = 1, β 2 = 1 for evaluation of power gain. In all simulation setting, we define β 1 and β 3 equal to zero.
Case 1: If we use the same level k 1 = k 2 for the two-stage procedures, then the level will be k 1 = k 2 = √ 1 − α as in Figure 2 .4. and k 1 = k 2 = 0.025.
Case 2: If we consider the level only for the second stage, then this implies k 1 = 0, k 2 = α. This implies that we only use the model (2.1). We set α = 0.05 in Table 3 .2. Table 3 .1 reports that, in most cases, the size of the test is approximately less than 0.05, the aimed significance level and there exists power gain at the indirect effect of the treatment. However, if we consider only the proportional hazards model as in (2.1), the result in Table 3 .2 shows that we couldn't expect the power gain due to indirect effect although we control the overall significance level at the level 0.05.
